INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
Stocks in this Quantisnow insightHealth Care
Historical context for INMB
Across the 29 sessions after earlier INMB headlines, the stock closed higher 17 times and lower 11 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INMB | SPY |
|---|---|---|---|
| Oct 21, 2026 | INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar | +0.6% | +0.5% |
| Oct 6, 2026 | INmune Bio to Attend the 2026 Maxim Growth Summit | -3.6% | +0.5% |
| Sep 14, 2026 | INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board | +5.0% | -0.4% |
| Sep 9, 2026 | INmune Bio to Present at the H.C. Wainwright Global Investment Conference | -2.0% | -0.5% |
| Aug 26, 2026 | INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings | +0.6% | +0.0% |
| Aug 7, 2026 | INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress | +9.2% | +0.6% |
Quantisnow market dataNASDAQ
INMB
INmune Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Get push alerts for INMB
Full INMB profile on Quantisnow Follow INMB and get a push notification the moment its next story breaks.